These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22194527)

  • 1. TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.
    Samimi G; Ring BZ; Ross DT; Seitz RS; Sutherland RL; O'Brien PM; Hacker NF; Huh WK
    Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):273-9. PubMed ID: 22194527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.
    Ring BZ; Murali R; Soslow RA; Bowtell DDL; Fereday S; deFazio A; Traficante N; Kennedy CJ; Brand A; Sharma R; Harnett P; Samimi G;
    Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):680-688. PubMed ID: 29531130
    [No Abstract]   [Full Text] [Related]  

  • 3. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
    Carser JE; Quinn JE; Michie CO; O'Brien EJ; McCluggage WG; Maxwell P; Lamers E; Lioe TF; Williams AR; Kennedy RD; Gourley C; Harkin DP
    Gynecol Oncol; 2011 Dec; 123(3):492-8. PubMed ID: 21920589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
    Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
    Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness.
    Shon W; Jenkins SM; Ross DT; Seitz RS; Beck RA; Ring BZ; Okuno SH; Gibson LE; Folpe AL
    J Cutan Pathol; 2011 Dec; 38(12):961-6. PubMed ID: 22050093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.
    Bartlett JM; Nielsen TO; Gao D; Gelmon KA; Quintayo MA; Starczynski J; Han L; Burnell MJ; Levine MN; Chen BE; Shepherd LE; Chapman JW;
    Br J Cancer; 2015 Sep; 113(5):722-8. PubMed ID: 26284338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment.
    Skírnisdóttir I; Seidal T
    Oncol Rep; 2012 Mar; 27(3):741-7. PubMed ID: 22159712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
    Skírnisdóttir I; Lindborg K; Sorbe B
    Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
    Ignatov T; Eggemann H; Costa SD; Roessner A; Kalinski T; Ignatov A
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1457-63. PubMed ID: 24825122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
    Du J; Li B; Fang Y; Liu Y; Wang Y; Li J; Zhou W; Wang X
    BMC Cancer; 2015 Jul; 15():536. PubMed ID: 26198101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Du XL; Parikh RC; Lairson DR; Giordano SH; Cen P
    Med Oncol; 2013 Mar; 30(1):440. PubMed ID: 23307252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
    Paek J; Lee M; Nam EJ; Kim SW; Kim YT
    Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of chemotherapy in epithelial ovarian cancer.
    Markman M
    Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinosarcoma of the ovary: a case-control study.
    Rauh-Hain JA; Growdon WB; Rodriguez N; Goodman AK; Boruta DM; Schorge JO; Horowitz NS; del Carmen MG
    Gynecol Oncol; 2011 Jun; 121(3):477-81. PubMed ID: 21420726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
    Brieau B; Auzolle C; Pozet A; Tougeron D; Bouché O; Soibinet P; Coriat R; Prieux C; Lecomte T; Goujon G; Marthey L; Rougier P; Bonnetain F; Ducreux M; Taieb J; Zaanan A
    Dig Liver Dis; 2016 Apr; 48(4):441-5. PubMed ID: 26775096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
    Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
    Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.
    Wosnitzer MS; Domingo-Domenech J; Castillo-Martin M; Ritch C; Mansukhani M; Petrylack DP; Benson MC; McKiernan JM; Cordon-Cardo C
    J Urol; 2011 Nov; 186(5):2094-100. PubMed ID: 21944130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.